Affinity Asset Advisors LLC Sells 1,000,000 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Affinity Asset Advisors LLC reduced its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 41.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,400,000 shares of the company's stock after selling 1,000,000 shares during the period. Teva Pharmaceutical Industries accounts for approximately 4.1% of Affinity Asset Advisors LLC's portfolio, making the stock its 5th largest holding. Affinity Asset Advisors LLC owned approximately 0.12% of Teva Pharmaceutical Industries worth $30,856,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of TEVA. Gabelli Funds LLC lifted its holdings in Teva Pharmaceutical Industries by 99.2% in the fourth quarter. Gabelli Funds LLC now owns 367,500 shares of the company's stock worth $8,100,000 after buying an additional 183,000 shares during the period. Jump Financial LLC increased its holdings in shares of Teva Pharmaceutical Industries by 128.0% in the 4th quarter. Jump Financial LLC now owns 487,103 shares of the company's stock worth $10,736,000 after buying an additional 273,493 shares during the last quarter. AGP Franklin LLC purchased a new position in Teva Pharmaceutical Industries in the 4th quarter worth about $266,000. CreativeOne Wealth LLC bought a new position in shares of Teva Pharmaceutical Industries in the 4th quarter worth $869,000. Finally, Mariner LLC grew its position in Teva Pharmaceutical Industries by 10.6% during the 4th quarter. Mariner LLC now owns 59,356 shares of the company's stock worth $1,308,000 after purchasing an additional 5,689 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Stock Up 1.3 %

Shares of Teva Pharmaceutical Industries stock traded up $0.18 during trading hours on Friday, hitting $13.61. 8,836,138 shares of the company's stock traded hands, compared to its average volume of 9,903,611. The company has a market cap of $15.43 billion, a PE ratio of -9.38, a PEG ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a twelve month low of $12.47 and a twelve month high of $22.80. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The stock has a 50 day simple moving average of $15.51 and a 200-day simple moving average of $17.70.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on TEVA. StockNews.com lowered shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Monday. Barclays cut their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. UBS Group decreased their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Bank of America decreased their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. Finally, Piper Sandler lifted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of "Moderate Buy" and an average target price of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.